KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinomaNikolaj Frost, Christian Grohé, Michael Hummel et al.|Translational Lung Cancer Research|2021Cited by 60